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Abstract
Background—Most mouthwashes contain alcohol, a known cause of head and neck cancer (oral 
cavity, pharynx, larynx), likely through the carcinogenic activity of acetaldehyde, formed in the 
oral cavity from alcohol.
Methods—We conducted a pooled analysis of 8,981 cases of head and neck cancer and 10,090 
controls from 12 case-control studies with comparable information on mouthwash use in the 
International Head and Neck Cancer Epidemiology Consortium. Logistic regression was used to 
assess the association of mouthwash use with cancers of the oral cavity, oropharynx, hypopharynx, 
and larynx, adjusting for study, age, sex, pack-years of tobacco smoking, number of alcoholic 
drinks/day, and education.
Results—Compared with never users of mouthwash, the odds ratio (OR) of all head and neck 
cancers was 1.01 (95% confidence interval [CI] 0.94, 1.08) for ever users, based on 12 studies. 
The corresponding ORs of cancer of oral cavity and oropharynx were 1.11 (95% CI 1.00, 1.23) 
and 1.28 (95% CI 1.06 1.56), respectively. OR for all head and neck cancer was 1.15 (95% CI 
1.01, 1.30) for use for more than 35 years, based on seven studies (p for linear trend=0.01), and 
OR 1.31 (95% CI 1.09 1.58) for use > 1 per day, based on five studies (p for linear trend <0.001).
Conclusions—Although limited by the retrospective nature of the study and the limited ability 
to assess risks of mouthwash use in non-users of tobacco and alcohol, this large investigation 
reveals potential risks for head and neck cancer sub-sites and in long-term and frequent users of 
mouthwash.
Impact—This pooled analysis provides the most precise estimate of the association between 
mouthwash use and head and neck cancer.
Introduction
An association between mouthwash use and head and neck cancer risk has been investigated 
in case-control studies conducted in the United States, Europe and Latin America [1–6]. 
Several systematic reviews and meta-analyses have detected an association [7], but 
confounding and other forms of bias could not be excluded. Many mouthwashes contain 
alcohol, typically in the order of 20%; alcohol is an established oral carcinogen, adding 
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credibility to the observed association [8]. We sought to provide more definitive evidence on 
the presence or absence of an association between mouthwash use and head and neck cancer 
using individual-level data on a very large number of cases and controls. Our approach 
presents two advantages over meta-analyses. First, we could use standard methods to control 
for confounding, while meta-analyses are limited to summary effect estimates reported in 
the original studies, which may not adequately control for confounders. Second, we used 
data from all studies with questionnaire items about mouthwash use in the International 
Head and Neck Cancer Epidemiology Consortium (INHANCE) [9], while meta-analyses are 
usually based on studies that have been published in journals and are potentially distorted by 
publication bias.
Material and methods
We used pooled data (version 1.5) from INHANCE [9] to assess the association between 
head and neck cancer and use of mouthwash among 8,981 cases (83.0% confirmed 
squamous cell carcinomas) and 10,090 controls from nine studies conducted in United 
States, two studies from Latin America and one international study. Selected characteristics 
of the studies are reported in Supplement Table 1. Controls were obtained from random digit 
dialling (3 studies), lists of residents or similar records (3 studies), hospital patients (4 
studies), blood donors (one study) and mixed sources (one study). In most studies controls 
were frequency-matched to cases based on age and sex. Although the exact wording of 
questions on mouthwash use differed across studies, questions were conceptually similar. 
For five of the 12 studies, results on mouthwash use have been previously reported, at least 
for some of the subjects [1–6], and were included in reviews and meta-analyses. The studies 
not previously reported on contribute 3,870 cases to the current analysis (43% of the total). 
Cases were categorized by tumor site (oral cavity, N=2,790; oropharynx, N=2,632; 
hypopharynx, N=577; larynx, N=1,793). Subjects with missing information on age, sex or 
mouthwash use were excluded, while subjects with missing data on tobacco smoking 
(0.9%), alcohol drinking (4.7%) and education level (2.8%) were included in separate 
categories in the regression models.
We estimated odds ratios (OR) and 95% confidence intervals (CI) for use of mouthwash, 
using logistic regression. In addition to ever-use, we considered regular mouthwash use, 
duration of use, and daily frequency of use; these indicators of extent of exposure were 
available for only some of the studies (details available in Supplement Table 1). In all 
analyses, never-users of mouthwash comprised the referent (unexposed) category. Linear 
trends in duration and frequency of use were assessed by examining p-values obtained from 
modeling the continuous forms of those variables. All analyses were performed using 
STATA Version 12.1 [17]. All ORs were adjusted for study (and center for multicenter 
studies), sex, age (nine groups), education (six categories), amount of alcohol drinking (five 
categories), and cumulative tobacco smoking (pack-years; seven categories). Stratified 
analyses were conducted by study, sex, cumulative tobacco smoking and amount of alcohol 
drinking. Separate analyses were conducted for cancers of specific sites within the head and 
neck (oral cavity, oropharynx, hypopharynx, larynx), as well as for duration and frequency 
of mouthwash use. Information on alcohol content in mouthwash was available from five 
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US-based studies, and most of the products used in these studies contained alcohol: 
therefore, we were not able to separate the effect of mouthwash with and without alcohol.
Results
Selected characteristics of the study population are reported in Supplement Table 2. Men 
comprised 74.3% of cases and 69.6% of controls; mean age was 58.4 (sd 10.7) in cases and 
57.9 (sd 11.5) in controls. The prevalence of ever mouthwash use among controls was 42.7% 
(study-specific range 13.2% to 63.4%, Supplement Table 3); the prevalence of ever-use was 
higher in heavy smokers (48.6% among controls who smoked more than 50 pack-years), and 
it was lower in non-drinkers and in heavy alcohol drinkers (36.8% of non-drinkers and 
27.3% of drinkers of 5 or more drinks/day).
The OR of head and neck cancer for ever-use of mouthwash was 1.01 (95% CI 0.94, 1.08); 
the corresponding OR of oral cavity cancer was 1.11 (95% CI 1.00, 1.23) (Table 1). The OR 
of cancers of other sites ranged from 0.70 to 1.22. Study-specific OR for all sites ranged 
from 0.42 to 1.86 (p-value of the test of heterogeneity <0.001) (Supplement Table 3). The 
OR of head and neck cancer for ever mouthwash use among never smokers was 0.95 (95% 
CI 0.83, 1.10), that among non-drinkers was 0.81 (95% CI 0.68, 0.97). Among subjects who 
did not smoke and did not drink (364 cases and 1,543 controls), the OR for mouthwash use 
was 0.83 (95% CI 0.66, 1.06). The OR of head and neck cancer for ever-use of mouthwash 
increased up to 30 pack-years, and decreased after that level of cumulative smoking (Figure 
1). No clear pattern was shown in the analysis according to amount of alcohol drinking 
(Supplemental Figure 1).
The OR of head and neck cancer for regular mouthwash use (2,612 cases [72% of ever-used] 
and 2,922 controls [68% of ever-used]; see Supplemental Table 1 for definition) was 1.02 
(95% CI 0.94, 1.11). Information on duration of mouthwash use was available in seven 
studies (1,369 cases and 1,514 controls among users); data on daily frequency of mouthwash 
use in five studies (4,535 cases and 4,584 controls among users). The OR was higher in the 
categories with longer duration (36+ years: OR 1.15, CI 1.01–1.30, p for trend 0.01) and 
higher frequency of use (>1 per day vs. never users: OR 1.31, CI 1.09–1.58, p for trend 
<0.001) than in the other categories (Table 2). Results for oral cavity cancer were similar to 
those for head and neck cancer; among users of mouthwash for more than 35 years the OR 
for oral cavity cancer was 1.28 (95% CI 1.06, 1.56). Compared with never-users of 
mouthwash, the OR of head and neck cancer for use of mouthwash twice/day or more for 
more than 35 years (two studies; 98 cases, 94 controls) was 1.75 (95% CI 1.25, 2.48).
We repeated the analysis for duration and frequency of mouthwash use among never 
smokers and non drinkers. The ORs for 35 or more years of mouthwash use were 1.12 (95% 
CI 0.85–1.49) among never smokers, 0.96 (95% CI 0.66–1.39) among non drinkers, and 
1.36 (95% CI 0.79–2.33) among those who did not smoke and did not drink. Corresponding 
ORs for higher frequency of use (>1 per day) were OR 0.86 (95% CI 0.60–1.22), 0.57 (95% 
CI 0.39–0.83), and 0.48 (95% CI 0.28–0.82).
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Stratification by region might account for difference in the prevalence of other risk factors of 
head and neck cancer; however, such analysis was hampered by the fact that most studies 
included in the pooled analysis had been conducted in United States; the OR for ever 
mouthwash use in this group of studies was 0.99 (95% CI 0.72–1.07).
Discussion
Our pooled analysis of twelve case-control studies provided evidence for an association of 
long-term and high-dose use of mouthwash with the risk of head and neck cancer, 
potentially related to alcohol content of many of these products.
Some of our results, however, are not supportive of a causal interpretation. We found no 
association of mouthwash use with head and neck cancer among never-smokers or never-
drinkers, suggesting no effect independent from that of these two habits. We did not observe 
greater risks for regular use compared to ever use, recognizing that most users were regular 
users. We assessed mouthwash related-risks with respect to categories of tobacco smoking. 
If alcohol in mouthwash is a determinant of risk, we might expect interaction with tobacco 
use, similar to that found for alcoholic beverages [18], but we found no evidence for this 
(Figure 1).
Our study built on a large population of cases and controls, and resulted in statistically more 
precise risk estimates overall and the ability to analyze specific subgroups such as non-
smokers and non-drinkers. Compared to previous meta-analyses, our pooled analysis of 
individual-patient data allowed more flexibility in the analytic approach, leading potentially 
to more stable effect estimates [19]. Although the study includes all available reports, the 
investigation is in the case-control setting, subject to random misclassification errors of self-
reported data over a lifetime, limited by absence of information on mouthwash alcohol 
content and potentially subject to reporting biases or actual mouthwash differentials related 
to case status.
In conclusion, the results of this pooled analysis confirm recent systematic reviews and 
meta-analyses [3, 20] and multicenter studies [21] that reported no overall increased risk of 
head and neck cancer in individuals who ever used mouthwash, but an association in long-
term frequent users. The study is limited by significant methodological issues, yet reveals 
potential risks for head and neck cancer sub-sites and in long-term and frequent users of 
mouthwash. No prospective cohort studies have been conducted on mouthwash use and oral 
cancer; these studies would avoid some of the potential biases inherent in the case-control 
design.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding
Boffetta et al. Page 5
Eur J Cancer Prev. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The INHANCE Consortium was supported by NIH grants NCI R03CA113157 and NIDCR R03DE016611. Studies 
participating in the pooled analysis were supported by grants:
• New York multicenter: NIH [P01CA068384 K07CA104231]
• Seattle (1985–1995): NIH [R01CA048996, R01DE012609]
• North Carolina (1994–1997): NIH [R01CA061188], and in part by a grant from the National Institute of 
Environmental Health Sciences [P30ES010126]
• Los Angeles: NIH [P50CA090388, R01DA011386, R03CA077954, T32CA009142, U01CA096134, 
R21ES011667] and the Alper Research Program for Environmental Genomics of the UCLA Jonsson 
Comprehensive Cancer Center
• Puerto Rico: jointly funded by National Institutes of Health (NCI) US and NIDCR intramural programs
• Latin America: Fondo para la Investigacion Cientifica y Tecnologica (FONCYT) Argentina, IMIM 
(Barcelona), Fundaco de Amparo à Pesquisa no Estado de Sao Paulo (FAPESP) [No 01/01768-2], and 
European Commission [IC18-CT97-0222]
• IARC Multicenter: Fondo de Investigaciones Sanitarias (FIS) of the Spanish Government [FIS 97/0024, 
FIS 97/0662, BAE 01/5013], International Union Against Cancer (UICC), and Yamagiwa-Yoshida 
Memorial International Cancer Study Grant
• US multicenter: The Intramural Program of the NCI, NIH, United States
• MSKCC: NIH [R01CA051845]
• Baltimore: NIH [DE016631]
• Hotspot: Johns Hopkins Richard Gelb Cancer Prevention Award
References
1. Wynder EL, Kabat G, Rosenberg S, Levenstein M. Oral cancer and mouthwash use. J Natl Cancer 
Inst. 1983; 70:255–60. [PubMed: 6571934] 
2. Kabat GC, Hebert JR, Wynder EL. Risk factors for oral cancer in women. Cancer Res. 1989; 
49:2803–6. [PubMed: 2713863] 
3. Winn DM, Diehl SR, Brown LM, Harty LC, Bravo-Otero E, Fraumeni JF Jr, Kleinman DV, Hayes 
RB. Mouthwash in the etiology of oral cancer in Puerto Rico. Cancer Causes Control. 2001; 
12:419–29. [PubMed: 11545457] 
4. Fernandez Garrote L, Herrero R, Ortiz Reyes RM, Vaccarella S, Anta JL, Ferbeye L, Munoz N, 
Franceschi S. Risk factors for cancer of the oral cavity and oro-pharynx in Cuba. Brit J Cancer. 
2001; 85:46–54. [PubMed: 11437401] 
5. Guha N, Boffetta P, Wunsch Filho V, Eluf Neto J, Shangina O, Zaridze D, Curado MP, Koifman S, 
Matos E, Menezes A, Szeszina-Dabrowska N, et al. Oral health and risk of squamous cell 
carcinoma of the head and neck and esophagus: results of two multicentric case–control studies. Am 
J Epidemiol. 2007; 166:1159–73. [PubMed: 17761691] 
6. Divaris K, Olshan AF, Smith J, Bell ME, Weissler MC, Funkhouse WK, Bradshaw PT. Oral health 
and risk for head and neck squamous cell carcinoma: the Carolina Head and Neck Cancer Study. 
Cancer Causes Control. 2010; 21:567–75. [PubMed: 20049634] 
7. La Vecchia C. Mouthwash and oral cancer risk: an update. Oral Oncol. 2009; 45:198–200. 
[PubMed: 18952488] 
8. Lachenmeier DW, Gumbel-Mako S, Sohnius EM, Keck-Wilhelm A, Kratz E, Mildau G. Salivary 
acetaldehyde increase due to alcohol-containing mouthwash use: a risk factor for oral cancer. Int J 
Cancer. 2009; 125:730–5. [PubMed: 19444911] 
9. Conway DI, Hashibe M, Boffetta P, Wunsch-Filho V, Muscat J, LaVecchia C, Winn DM. INHANCE 
Consortium. Enhancing epidemiologic research on head and neck cancer: INHANCE - The 
international head and neck cancer epidemiology consortium. Oral Oncol. 2009; 45:743–6. 
[PubMed: 19442571] 
10. Rogers MA, Thomas DB, Davis S, Vaughan TL, Nevissi AE. A case-control study of element 
levels and cancer of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev. 1993; 
2:305–12. [PubMed: 8348053] 
Boffetta et al. Page 6
Eur J Cancer Prev. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
11. Rosenblatt KA, Daling JR, Chen C, Sherman KJ, Schwartz SM. Marijuana use and risk of oral 
squamous cell carcinoma. Cancer Res. 2004; 64:4049–54. [PubMed: 15173020] 
12. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. 
Case-control study of Human Papilloma virus and oropharyngeal cancer. N Engl J Med. 2007; 
356:1944–56. [PubMed: 17494927] 
13. Muscat JE, Richie JP Jr, Thompson S, Wynder EL. Gender differences in smoking and risk for oral 
cancer. Cancer Res. 1996; 56:5192–97. [PubMed: 8912856] 
14. Schantz SP, Zhang ZF, Spitz MS, Sun M, Hsu TC. Genetic susceptibility to head and neck cancer: 
interaction between nutrition and mutagen sensitivity. Laryngoscope. 1997; 107:765–81. 
[PubMed: 9185733] 
15. Cui Y, Morgenstern H, Greenland S, Tashkin DP, Mao J, Cao W, Cozen W, Mack TM, Zhang ZF. 
Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and squamous cell 
carcinomas of the oropharynx, larynx and esophagus. Int J Cancer. 2006; 118:714–20. [PubMed: 
16094634] 
16. Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, 
Rose B, Pintos J, Fernandez L, Idris A, et al. Human papillomavirus and the risk of Human 
Papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter 
study. J Natl Cancer Inst. 2003; 95:1772–83. [PubMed: 14652239] 
17. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP; 2011. 
18. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, 
Daudt AW, Fabianova E, Fernandez F, Wunsch-Filho V, et al. Interaction between tobacco and 
alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and 
Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009; 18:541–50. 
[PubMed: 19190158] 
19. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, 
meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999; 28:1–9. [PubMed: 
10195657] 
20. Gandini S, Negri E, Boffetta P, La Vecchia C, Boyle P. Mouthwash and oral cancer risk quantitative 
meta-analysis of epidemiologic studies. Ann Agric Environ Med. 2012; 19:173–80. [PubMed: 
22742785] 
21. Ahrens W, Pohlabeln H, Foraita R, Nelis M, Lagiou P, Lagiou A, Bouchardy C, Slamova A, 
Schejbalova M, Merletti F, Richiardi L, Kjaerheim K, et al. Oral health, dental care and 
mouthwash associated with upper aerodigestive tract cancer risk in Europe: the ARCAGE study. 
Oral Oncol. 2014; 50:616–25. [PubMed: 24680035] 
Boffetta et al. Page 7
Eur J Cancer Prev. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Odds ratio for ever mouthwash use and head and neck cancer risk, stratified by cumulative 
tobacco smoking, INHANCE Consortium
OR, odds ratio for ever vs. never use of mouthwash, adjusted for study center, age, sex, 
education level, average amount of alcohol drinking.
CI, confidence interval.
NS, never smokers.
Boffetta et al. Page 8
Eur J Cancer Prev. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Boffetta et al. Page 9
Ta
bl
e 
1
A
ss
oc
ia
tio
n 
of
 h
ea
d 
an
d 
ne
ck
 c
an
ce
r o
v
er
al
l a
nd
 b
y 
sit
e 
w
ith
 ev
er
 u
se
 o
f m
ou
th
w
as
h,
 IN
H
A
N
CE
 C
on
so
rti
um
Tu
m
o
r 
sit
e*
C
as
es
 (e
xp
/un
ex
p)
C
on
tr
o
ls 
(ex
p/u
ne
xp
)
a
O
R
95
%
 C
I
H
ea
d 
an
d 
ne
ck
36
11
/5
37
0
43
08
/5
78
2
1.
01
0.
94
, 1
.0
8
O
ra
l c
av
ity
11
67
/1
62
3
42
88
/5
73
2
1.
11
1.
00
, 1
.2
3
O
ro
ph
ar
yn
x
12
84
/1
34
8
43
08
/5
78
2
1.
22
1.
10
, 1
.3
5
H
yp
op
ha
ry
nx
20
1/
37
6
37
39
/4
70
0
0.
78
0.
64
, 0
.9
6
La
ry
nx
48
3/
13
10
23
28
/3
41
7
0.
70
0.
60
, 0
.8
2
aO
R,
 o
dd
s r
at
io
 fo
r e
v
er
 v
s.
 n
ev
er
 m
o
u
th
w
as
h 
us
e,
 a
dju
ste
d f
or 
stu
dy
 ce
nte
r, a
ge
, s
ex
, 
cu
m
u
la
tiv
e 
to
ba
cc
o 
sm
ok
in
g 
(pa
ck
-ye
ars
), a
v
er
ag
e 
am
ou
nt
 o
f a
lc
oh
ol
 d
rin
ki
ng
, e
du
ca
tio
n 
le
v
el
.
CI
, c
on
fid
en
ce
 in
te
rv
al
.
*
IC
D
-O
-2
 c
od
es
: o
ra
l c
av
ity
,
 
C0
0.
3-
C0
0.
9,
 C
02
.0
-C
02
.3
, C
03
.0
, C
03
.1
, C
03
.9
, C
04
.0
, C
04
.1
, C
04
.8
, C
04
.9
, C
05
.0
, C
06
.0
-C
06
.2
, C
06
.8
, C
06
.9
; o
ro
ph
ar
yn
x,
 C
01
.9
, C
02
.4
, C
05
.1
, C
05
.2
, C
09
.0
, C
09
.1
, 
C0
9.
8,
 C
09
.9
, C
10
.0
-C
10
.4
, C
10
.8
, C
10
.9
; h
yp
op
ha
ry
nx
, C
12
.9
, C
13
.0
-1
3.
2,
 C
13
.8
, C
13
.9
; l
ar
yn
x,
 C
32
.0
-C
32
.3
, C
32
.8
-C
32
.9
Eur J Cancer Prev. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Boffetta et al. Page 10
Ta
bl
e 
2
A
ss
oc
ia
tio
n 
of
 h
ea
d 
an
d 
ne
ck
 c
an
ce
r w
ith
 d
ur
at
io
n 
an
d 
fre
qu
en
cy
 o
f u
se
 o
f m
ou
th
w
as
h,
 IN
H
A
N
CE
 C
on
so
rti
um
H
ea
d 
an
d 
ne
ck
 c
an
ce
r
O
ra
l c
av
ity
 c
an
ce
r
C
as
es
C
on
tr
o
ls
a
O
R
95
%
 C
I
C
as
es
C
on
tr
o
ls
a
O
R
95
%
 C
I
D
ur
at
io
n 
of
 u
se
 (y
ea
rs)
*
0 
(N
on
-us
ers
)
24
38
30
60
1.
00
R
ef
.
68
8
30
60
1.
00
R
ef
.
1–
15
64
0
94
8
0.
88
0.
77
, 1
.0
6
19
3
94
8
0.
95
0.
78
, 1
.1
6
16
–3
5
87
7
97
6
1.
13
1.
00
, 1
.2
8
25
1
97
6
1.
15
0.
96
, 1
.3
9
36
+
78
4
86
4
1.
15
1.
01
, 1
.3
0
24
7
86
4
1.
28
1.
06
, 1
.5
6
p-
va
lu
e 
of
 te
st 
fo
r l
in
ea
r t
re
nd
0.
01
0.
08
Fr
eq
ue
nc
y 
of
 u
se
 (t
im
es/
da
y)*
*
0 
(N
on
 us
ers
)
31
66
30
60
1.
00
R
ef
.
10
56
30
60
1.
00
R
ef
.
U
p 
to
 1
/d
ay
10
22
11
54
1.
23
1.
08
, 1
.4
0
28
8
11
54
1.
20
1.
00
, 1
.4
4
M
or
e 
th
an
 1
/d
ay
34
7
37
0
1.
31
1.
09
, 1
.5
8
12
2
37
0
1.
26
0.
98
, 1
.6
2
p-
va
lu
e 
of
 te
st 
fo
r l
in
ea
r t
re
nd
<
0.
00
1
0.
02
*
B
as
ed
 o
n 
da
ta
 fr
om
 si
x 
stu
di
es
 (s
ee
 Su
pp
lem
en
t T
ab
le
 1
 fo
r d
et
ai
ls)
.
*
*
B
as
ed
 o
n 
da
ta
 fr
om
 fi
v
e 
st
ud
ie
s (
see
 Su
pp
lem
en
t T
ab
le
 1
 fo
r d
et
ai
ls)
.
aO
R,
 o
dd
s r
at
io
, a
dju
ste
d f
or 
stu
dy
 ce
nte
r, a
ge
, s
ex
, 
du
ra
tio
n 
of
 to
ba
cc
o 
sm
ok
in
g,
 av
er
ag
e 
am
ou
nt
 o
f a
lc
oh
ol
 d
rin
ki
ng
, e
du
ca
tio
n 
le
v
el
.
CI
, c
on
fid
en
ce
 in
te
rv
al
.
R
ef
, r
ef
er
en
ce
 c
at
eg
or
y.
Eur J Cancer Prev. Author manuscript; available in PMC 2017 July 01.
